Keyphrases
Enoxaparin
100%
Feasible Strategy
100%
Critically Ill Patients
100%
Blood Clot
100%
Acute Kidney Injury
100%
Randomized Controlled Trial
100%
Once-daily
66%
Thromboprophylaxis
66%
Venous Thromboembolism
50%
Dialysis
33%
Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL)
33%
Continuous Renal Replacement Therapy
33%
Bleeding Risk
16%
Pharmacokinetics
16%
Interim Analysis
16%
Trial Registration
16%
Anti-factor Xa
16%
EudraCT
16%
March 2013
16%
Urine Output
16%
Urine Volume
16%
A-level
16%
Double-blind Randomized Controlled Trial
16%
Free Interval
16%
Relative Risk
16%
Prognostic Factors
16%
Resource Utilization
16%
Intensive Care Unit
16%
Intensive Care Unit Patients
16%
Bleeding
16%
Critically Ill
16%
Control Arm
16%
Method Design
16%
Denmark
16%
Length of Stay
16%
Medicine and Dentistry
Blood Clot
100%
Randomized Controlled Trial
100%
Acute Kidney Injury
100%
Thromboprophylaxis
80%
Venous Thromboembolism
60%
Continuous Renal Replacement Therapy
40%
Intensive Care Unit
40%
Neutrophil Gelatinase Associated Lipocalin
40%
Lifespan
20%
Pharmacokinetic
20%
Interim Analysis
20%
Prothrombinase
20%
Heparin-Induced Thrombocytopenia
20%
Prognostic Factor
20%
Clinical Trial
20%
Arm
20%
Bleeding
20%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Acute Kidney Failure
100%
Enoxaparin
100%
Venous Thromboembolism
50%
Replacement Therapy
33%
Neutrophil Gelatinase Associated Lipocalin
33%
Blood Clotting Factor 10a
16%
Heparin Induced Thrombocytopenia
16%
Pharmacokinetic
16%
Clinical Trial
16%
Bleeding
16%